Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argent Biopharma (RGTLF)
OTHER OTC:RGTLF
Holding RGTLF?
Track your performance easily
RGTLF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.10 - $0.80
Previous Close$0.18
Volume10.00
Average Volume (3M)159.56K
Market Cap
$9.99M
Enterprise Value$9.78M
Total Cash (Recent Filing)AU$702.87K
Total Debt (Recent Filing)AU$1.04M
Price to Earnings (P/E)―
Beta-4.98
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding3,198,519
10 Day Avg. Volume2
30 Day Avg. Volume159,558
Standard Deviation0.43
R-Squared0.00059
Alpha-0.00649
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)102.63
Price to Cash Flow (P/CF)-23.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Argent Biopharma News
PremiumCompany Announcements
Argent BioPharma’s Strategic Moves and Collaboration
PremiumCompany Announcements
Argent BioPharma Issues New Shares Amidst Strategic Growth
PremiumCompany Announcements
Argent Biopharma Lists New Shares on ASX
PremiumCompany Announcements
Argent BioPharma Prepares for Annual General Meeting
PremiumCompany Announcements
Argent BioPharma Secures Funding for Drug Development
PremiumCompany Announcements
Argent Biopharma Announces New Major ShareholderPremiumCompany Announcements
Argent Biopharma Director Bolsters Share Holdings
PremiumCompany Announcements
Argent BioPharma Issues New Shares, Ensures ComplianceOptions Prices
Currently, No data available
---
Ownership Overview
RGTLF FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest stock price was $0.10 and its highest was $0.80 in the past 12 months.
What is Argent Biopharma’s market cap?
Currently, no data Available
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Feb 26, 2025 which is in 97 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Aug 30, 2024. The company reported -$0.149 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.149.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 54,272,270 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -$0.149 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -25.926%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in RGTLF
---
Argent Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
RGTLF Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Bought Shares
Worth $325.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-67.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.41%
Trailing 12-Months
Company Description
Argent Biopharma
MGC Pharmaceuticals Ltd is a European-based specialist Medical Cannabis company, in Phytocannabinoid-based medicine within the biopharmaceutical industry. The company's principal business goal is to produces and supply quality Cannabinoid based pharmaceutical products for the emergent medical markets in Europe, North America and Australasia.
---
Technical Analysis
---